Esperion enters RIPA amendment with $50M partial call, waiver of defaults

Esperion Therapeutics, Inc.

One-time partial call of $50M on Revenue Interests under amended Revenue Interest Purchase Agreement.
Cumulative Purchaser Payments reduced to $177,777,778.
Waived certain claimed defaults, breaches and Put Option Events related to new bank account.
Other material terms of RIPA and Security Agreement remain unchanged.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Esperion Therapeutics, Inc. amended Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement with the purchasers party thereto and Eiger III SA LLC valued at $50 million (effective 2022-11-23).

Action: amendment
Counterparty: the purchasers party thereto and Eiger III SA LLC
Value: $50 million
Effective: 2022-11-23

Exact text from the filing

On November 23, 2022, Esperion Therapeutics, Inc. (the “Company”) entered into Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (the “RIPA Amendment”), by and among the Company, the purchasers party thereto (the “Purchasers”), and Eiger III SA LLC, as the collateral agent and administrative agent (the “Purchaser Agent”), which amends (i) the Revenue Interest Purchase Agreement

View on SEC.gov

Browse all material agreements →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-121726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.